Sernova Corp
TSX VENTURE : SVA

Sernova Corp

October 23, 2006 09:30 ET

Sernova's Research Following Latest NIH Guidelines for Type 1 Diabetes

KELOWNA, BRITISH COLUMBIA--(CCNMatthews - Oct. 23, 2006) - Sernova Corp.'s ("Sernova") (TSX VENTURE:SVA) cell replacement research for the company's diabetes product development project is in line with the recently released recommendations of the US National Institute of Health's ("NIH") long range plan for diabetes research.

Entitled "Advances and Emerging Opportunities in Type 1 Diabetes Research: A Strategic Plan", one of NIH's stated goals is the development of new and improved cell replacement therapies - exactly the focus of Sernova's diabetes research.

The NIH plan recognizes the advances pioneered by the Edmonton Protocol, but the plan identified four barriers preventing cell replacement from becoming a viable treatment for a large number of diabetics. Current research by Sernova Corp. demonstrates its technology may overcome those key barriers described below:



---------------------------------------------------------------------
NIH Noted Barrier Sernova Solution
---------------------------------------------------------------------
Develop methods to produce an Use virtually unlimited supply of pig
unlimited supply of islets cells, (Pig insulin is compatible
with humans)
---------------------------------------------------------------------
Improve ways to harvest islets Size of pig cell supply allows
harvesting to be less than optimally
efficient without any noticeable
economic impact or timing delays
---------------------------------------------------------------------
Reduce complication of islet Small device for containing cells is
transplantation implanted just below the skin in a
10 minute operation under local
anaesthetic
---------------------------------------------------------------------
Prevent recurrent autoimmunity When Sernova's patented Sertoli cells
and the immune rejection of are transplanted with the islets in
donor islets the device, a naturally protected,
immunoprivileged site is created
which minimizes or eliminates the
body's immune response to the foreign
cells
---------------------------------------------------------------------


Stated Sernova President Justin Leushner, "The NIH's plan underscores the importance of developing an effective and commercially viable cell replacement therapy for insulin dependent diabetes. We believe our research and technology will lead to the breakthrough NIH envisions."

Sernova's research is currently compiling pre-clinical data to support an Investigational New Drug application to the United States Food and Drug Administration. The Company owns the exclusive rights to over 20 patents related to the therapeutic use of Sertoli cells.

About Sernova

Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications.

This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

ON BEHALF OF THE BOARD

Justin Leushner, President


Contact Information